Health Value, Virgen de Aranzazu, 21, 28034 Madrid, Spain.
Expert Opin Pharmacother. 2010 Apr;11(6):877-87. doi: 10.1517/14656561003649555.
The recent increase in the use of antineoplastic and immune suppressive agents and the use of broad-spectrum antibiotics, prosthetic interventions, organ transplants and more aggressive surgery have been related to a greater prevalence of invasive fungal infections (IFI). Over the past few years, several new antifungal therapies have become available for these patients. Pharmacoeconomic data can play a useful role in comparing the relative benefits of treatment.
This review summarizes all the available evidence regarding the pharmacoeconomics of voriconazole. A systematic review of pharmacoeconomic analyses through a non-restricted literature search was conducted (until May 2009).
The reader will gain a greater understanding of the pharmacoeconomics role of voriconazole.
The majority of economic analyses have shown that voriconazole is a more cost-effective alternative in the treatment of invasive fungal infections than the antifungal drugs with which it was compared.
最近抗肿瘤和免疫抑制药物的使用以及广谱抗生素、人工介入、器官移植和更激进的手术的使用与侵袭性真菌感染（IFI）的更高发生率有关。在过去的几年中，已经有几种新的抗真菌疗法可用于这些患者。药物经济学数据在比较治疗的相对益处方面可以发挥有用的作用。
本文综述了所有关于伏立康唑药物经济学的现有证据。通过非限制文献检索对药物经济学分析进行了系统综述（截至 2009 年 5 月）。
读者将获得什么读者将更深入地了解伏立康唑的药物经济学作用。
大多数经济分析表明，与比较的抗真菌药物相比，伏立康唑在治疗侵袭性真菌感染方面是一种更具成本效益的选择。
